ANTI-CD19

Clinical trials for ANTI-CD19 explained in plain language.

Never miss a new study

Get alerted when new ANTI-CD19 trials appear

Sign up with your email to follow new studies for ANTI-CD19, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New antibody drug aims to boost platelets in Hard-to-Treat ITP

Disease control Recruiting now

This early-phase trial is testing a new drug called budoprutug (TNT119) in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive two IV doses and are monitored for safety, how the drug mov…

Matched conditions: ANTI-CD19

Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:00 UTC

ANTI-CD19

Get alerted when new ANTI-CD19 trials appear

New antibody drug aims to boost platelets in Hard-to-Treat ITP